Targeting the EWS-FLI1 transcription factor in Ewing sarcoma.

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Ewing sarcoma is a rare bone cancer with limited treatment options.
• Preclinical studies suggest a synergistic effect between trabectedin and irinotecan.
• This combination targets the EWS-FLI1 transcription factor, crucial in Ewing sarcoma development.

Observation:

• A single patient with advanced Ewing sarcoma, progressing on standard therapies, received sequential trabectedin and irinotecan.
• The treatment regimen involved trabectedin infusion followed by irinotecan, administered every three weeks.
• The patient experienced transient side effects, including hematological toxicity and elevated liver enzymes.

Findings:

• Disease stabilization was achieved for 11 treatment courses.
• The patient showed clinical improvement and a reduced need for opioid pain relief.
• Sudden death occurred before the 12th course, deemed unrelated to the drug treatment.

Implications:

• The combination of trabectedin and irinotecan demonstrates encouraging clinical benefit and good tolerability in Ewing sarcoma.
• This therapeutic strategy warrants further clinical investigation for Ewing sarcoma patients.
• Targeting EWS-FLI1 may represent a viable approach in Ewing sarcoma treatment.